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Abstract
Background: Target selection for oncology is a crucial step in the successful development of therapeutics.
Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing of specific loci offers an alternative
method to RNA interference and small molecule inhibitors for determining whether a cell line is dependent on a
specific gene product for proliferation or survival. In our initial studies using CRISPR-Cas9 to verify the dependence
on EZH2 activity for proliferation of a SMARCB1/SNF5/INI1 mutant malignant rhabdoid tumor (MRT) cell line, we
noted that the initial reduction in proliferation was lost over time. We hypothesized that in the few cells that retain
proliferative capacity, at least one allele of EZH2 remains functional. To verify this, we developed an assay to analyze
10s-100s of clonal cell populations for target gene disruption using restriction digest and fluorescent fragment
length analyses.
Results: Our results clearly show that in cell lines in which EZH2 is essential for proliferation, at least one potentially
functional allele of EZH2 is retained in the clones that survive.
Conclusion: This assay clearly indicates whether or not a specific gene is essential for survival and/or proliferation
in a given cell line. Such data can aid the development of more robust therapeutics by increasing confidence in
target selection.
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Background
Despite large scale genomic sequencing efforts [1, 2],
translation of the resulting data into successful treat-
ment in the clinic has been difficult. Furthermore, many
targets reported in the literature to be drivers of cancer
have not been confirmed on further analysis [3, 4]. The
use of RNA interference (RNAi) for target validation
allows the effect of gene knockdown on proliferation to
be rapidly assessed ; however, these reagents might not
always lead to sufficient mRNA knockdown to evoke a
phenotypic effect. For example, an RNAi screen to
identify epigenetic dependencies found SMARCA2 as a
potential target in SMARCA4-mutant cell lines [5]. Yet
the screen failed to identify EZH2 in a SMARCB1 mu-
tant MRT cell line, G-401 [5], despite the fact that small-
molecule-mediated inhibition of EZH2 in this cell line
can induce cell death [6, 7]. Similarly, two independent
pooled shRNA screens in primary cells from mouse
models of MLL–AF9 acute myeloid leukemia (AML) did
not identify DOT1L as an essential enzyme for these tu-
mors [8, 9], even though Dot1l knockout mouse models
[10, 11] and a small molecule DOT1L inhibitor [12] have
indicated a requirement for DOT1L in MLL-driven
AML. These data imply that for certain classes of tar-
gets, nearly complete inhibition of enzyme function is
required to observe meaningful biological phenotypes.
The CRISPR (clustered regularly interspaced short pal-
indromic repeats)–Cas9 system allows for a rapid, cost-
effective and precise knockout of target genes through
the introduction of insertions/deletions (indels) [13–16],
and should therefore provide the necessary tools to ob-
serve phenotypes that require complete loss of protein
function. To test this hypothesis, we carried out a proof-
of-concept study using EZH2 as a target for CRISPR–
Cas9 mediated knockout in cell lines. EZH2 (Enhancer
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of Zeste 2) is the catalytic subunit of the polycomb
repressive complex 2 (PRC2) and has histone methyl-
transferase activity that catalyzes the mono-, di- and tri-
methylation of lysine 27 on histone 3 (H3K27) [17, 18].
Work using RNAi knockdown and small molecule in-
hibitors of EZH2 has shown that EZH2 is required
for the proliferation of EZH2 mutant lymphoma cells,
SMARCB1-deficient MRT cells and cells from other
cancer types [6, 7, 19–23].
As expected, the disruption of EZH2 by CRISPR–Cas9
at early time points led to a decrease in the proliferation
rate of an EZH2-dependent cell line, but not an EZH2-
independent cell line. However, after 2 weeks the
remaining cells in the EZH2-dependent cell line
expressed near wild-type levels of EZH2 and showed
comparable proliferation rates to a control cell line,
whereas the EZH2-independent cell line maintained low
levels of EZH2. This suggests that in the EZH2-
dependent cell line, the cells in which CRISPR–Cas9 has
successfully targeted EZH2 rapidly arrest and/or are lost
from the cell population, and that the cells that grow
out after two weeks are those in which EZH2 has not
been effectively targeted and thus retain at least one
functional copy of EZH2. If correct, this hypothesis indi-
cates that carrying out CRISPR–Cas9 studies for individ-
ual target genes without analyzing single cell clones
could produce misleading results. However, single cell
cloning can be time-consuming and a large number of
clonal cell populations need to be analyzed to derive ac-
curate conclusions owing to the heterogeneous geno-
types that could arise. Therefore, we have developed an
assay that allows for the rapid measurement of gene
knockout rates in 10’s–100’s of single cell clones. This
assay uses both restriction digest analysis and fluores-
cent undigested fragment length analysis to assess the
disruption status of each clone, with the assumption that
in a cell line for which a gene is required, very few (if
any) clones will emerge in which the gene of interest is
homozygously knocked out. Using this protocol we were
able to quickly and accurately assess EZH2 essentiality
in four cell lines, proving that the assay is an accurate,
quick and robust measure of gene essentiality. Import-
antly, this approach should be applicable to any target
gene of interest that is expected to affect cell prolifera-
tion or survival, thus providing a crucial insight into
gene essentiality and target identification.
Results
The Anti-Proliferative Effect of EZH2 Knockout does not
Persist in an EZH2-Dependent Cell Population
We and others have previously found that SMARCB1-
deficient but not SMARCB1-wild type MRT cell lines are
sensitive to inhibition of EZH2 [6, 7, 23]. The CRISPR–
Cas9 system allows for precise knockout of target genes
through the introduction of insertions/deletions (indels),
and provides the necessary tools to observe phenotypes
that require complete loss of protein [13–16]. To test
this approach, we carried out a proof-of-concept study
using EZH2 as a target for knockout in SMARCB1-
negative (G-401) MRT cell line and SMARCB1-wild
type (RD) rhabdomyosarcoma cell line; the former but not
latter are sensitive to inhibition of EZH2 [6, 7, 23]. As ex-
pected, CRISPR–Cas9 targeting of EZH2 led to a decrease
in EZH2 protein and levels of H3K27me3 in both the G-
401 and RD cells at 6 and 9 days post infection (Fig. 1a).
Knockout of EZH2 in G-401 cells also resulted in a de-
creased proliferation rate while the proliferation rate of
RD cells was not affected (Fig. 1b and c). These results are
concordant with our previously reported data using an
EZH2 inhibitor [6], and confirmed here with EPZ007210,
another highly selective and potent inhibitor of EZH2 ac-
tivity [24] (Fig. 1a and d and Additional file 1: Figure S1).
Thus, at an early time point following CRISPR–Cas9 gene
editing, the phenotypic outcome mirrors that of small
molecule inhibition in these cell lines.
Given the dependence of G-401 cells on EZH2 activity,
we investigated how cells behaved at later time points
after EZH2 knockout. Surprisingly, EZH2 expression
had already been restored to near control levels in the
G-401 but not RD cells by 15 or 21 days post-infection
(Fig. 1e), and the proliferation rate in the G-401 cells was
restored to approximately control levels (Fig. 1f and g). As
knockout results in a permanent and heritable loss of
EZH2, expression cannot be recovered post knockout.
Thus, these data suggest that the cells remaining at
later time points likely retain at least one functional
copy of EZH2. If this hypothesis is correct, the surviving
G-401 cells will either retain a wild-type allele of EZH2 or
will have in-frame indels that do not affect EZH2 protein
function. The DNA breaks made by Cas9 are repaired by
the imprecise non-homologous end joining DNA repair
pathway and some of these mutations could be in-frame
indels that retain function, as has been seen for other
genes [14, 25–27]. These results illustrate the potency of
CRISPR–Cas9 for the generation of gene knockouts and
also uncover some challenges with using CRISPR–Cas9 to
assess the consequences of the deletion of an essential
gene for target identification and validation.
Assay Work Flow Summary for Single Cell CRISPR–Cas9
Essentiality Assay
Based on the above data, we set out to design and test
an assay that would more rapidly and accurately allow
the use of CRISPR–Cas9 reagents to test the essentiality
of a single gene. After CRISPR–Cas9 targeting, our assay
is designed to examine 1) whether the cells that continue
to proliferate in a target-dependent cell line are those
that retain at least one in-frame allele (either edited or

















































Fig. 1 The anti-proliferative effect of EZH2 knockout does not persist in an EZH2-dependent cell population. G-401 and RD cells were infected
with a lentiviral vector encoding Cas9 and each of three sgRNAs targeting EZH2. a The western blots show that 6 and 9 days after infection, EZH2
protein levels are decreased in both the G-401 cells and RD cells compared with a control sgRNA targeting the hemoglobin 1 (HBE1) gene.
H3K27me3 levels are also decreased, whereas H3 levels are unchanged. The right hand panel indicates that treatment of G-401 cells and RD cells
with a small molecule inhibitor of EZH2 for 72 h also decreases H3K27me3 levels, but has no effect on the expression levels of EZH2 and H3 as
expected [6]. b, c Proliferation rate of cells from panel a. All 3 sgRNAs targeting EZH2 resulted in reduced rates of proliferation in G-401 cells and
had little effect on the proliferation rate of the RD cells. d Proliferation rate of cells from panel a treated with or without a small molecule inhibitor of
EZH2. e Western blot data showing that at 15 and 20 days post-infection, EZH2 expression levels are at near control levels in the G-401 cells infected
with one of three independent sgRNAs targeting EZH2. A recovery in the levels of H3K27me3 was also evident. At the same time points, EZH2 protein
expression remained low in RD cells infected with the same sgRNAs and H3K27me3 levels remained undetectable. f, g Proliferation rate of cells from
panel e. The decrease in proliferation rates induced by EZH2 knockout was no longer evident at 20 days post-infection in the G-401 cells,
while proliferation rates remain unaltered in RD cells expressing one of three independent sgRNAs targeting EZH2. All data in this figure are
representative of at least two independent experiments. Error bars show standard error mean for six technical replicates
Grassian et al. Biological Procedures Online  (2015) 17:15 Page 3 of 10
unedited) and 2) whether cells that continue to prolifer-
ate in target-independent cell line have alleles that are
mostly edited and have out-of-frame alterations. A com-
mon technique to study gene knockout phenotypes is to
examine single cell clones and we hypothesized that for
a cell line which is dependent on a certain gene, it
should be difficult, if not impossible, to generate clonal
homozygous knockouts for the gene of interest.
Conversely, in cell lines for which a large number of
homozygous knockout single cell clones are recovered, it
would be unlikely that the growth of that cell line is
dependent on the gene of interest. Therefore, we devel-
oped a protocol that allowed us to examine gene knock-
out rates in 10’s to 100’s of single cell clones in a
medium-throughput manner. This protocol also assesses
whether in-frame or out-of-frame alleles for the gene of
interest are produced. Thus, this assay allows for the
rapid assessment of gene essentiality.
The work-flow for this assay is shown in Fig. 2. In
brief, a sgRNA is chosen that has a Cas9 cleavage site
that overlaps with a restriction digest site, thus allowing
for rapid analysis for the presence of indels (as described
below). After virus infection, the cells are transduced
with lentivirus containing Cas9 and the sgRNA, and
selected with a relevant antibiotic for at least 2 weeks
before single cell dilution. This prolonged antibiotic selec-
tion ensures that the majority of the target alleles will have
been edited, and that colonies derived from the single cells
will be uniform. Wells with a single cell are marked and
colony growth is monitored until sufficient cell numbers
are present in the colony to enable assessment of the
knockout status by PCR-based techniques. Two medium-
throughput methods are then used to examine the zygos-
ity of the gene of interest in each of the isolated clones: re-
striction digest and fluorescent undigested fragment
length analysis. For the restriction digest, PCR primers are
chosen such that DNA fragments of unequal length are
produced if the restriction site remains intact (as illus-
trated in Fig. 2). Although the restriction digest assay can
provide an estimate for indel frequency, it does not cor-
rectly identify indels that do not result in alteration of the
restriction digest site, or for indels that abolish the site but
do not result in mis-sense or non-sense transcripts (e.g. in-
frame indels or single base alterations). Thus, fluorescent
fragment length analysis of the undigested PCR product is
also used to assess indel status. A fragment of wild-type
length suggests either a lack of disruption or in-frame
nucleotide alteration(s), whereas a fragment that is
not wild-type length indicates the presence of indels.
By combining these techniques, the assessment of
zygosity can be evaluated in a medium-throughput
manner in single cell clones and the functional status
of the gene of interest inferred. Importantly, this
technique should be applicable to any gene, with the
only requirements being the identification of a func-
tional sgRNA for the target gene and cell lines that
can form single cell clones.
Proof of Concept for Medium-Throughput Assay with EZH2
Four cell lines were used as a proof-of-concept for this
assay: EZH2 inhibitor insensitive RD cells (SMARCB1
wild-type), and the SMARCB1-negative cell lines G-401,
G-402 and KYM-1 which are dependent on EZH2 cata-
lytic activity for proliferation [6]. Having verified that
these cell lines could generate colonies from single cells
at a sufficient rate (Additional file 1: Table S1), each line
was infected with an EZH2 sgRNA and Cas9; this
sgRNA substantially reduces EZH2 expression and func-
tion (Fig. 1a; EZH2 sgRNA #3) with limited predicted
off-target cut sites (data not shown) and contains a
restriction digest site that spans the Cas9 cut site
(Additional file 1: Figure S2). Cells were grown in the
presence of puromycin for 17 days (by which time we
anticipate that gene editing would have proceeded to
completion at the EZH2 locus), followed by single cell
dilution.
We analyzed the colonies by restriction digest to
assess the allelic status of EZH2 (each of the cell lines
examined has two copies of EZH2, with the exception of
the RD cells which contain three copies). For the RD
cells (EZH2-independent), the majority of the clones
showed homozygous disruption at the EZH2 locus
(Fig. 3a and Additional file 1: Figure S3). However, for
the three EZH2-dependent cell lines, the majority of the
clones recovered had either unedited EZH2 alleles or
were heterozygous at this locus (one edited and one un-
edited allele) as assessed by restriction digest analysis
(Fig. 3b, c and d and Additional file 1: Figure S3). This
differential outgrowth suggests that in the EZH2-
dependent cell lines, at least one allele remains that is
likely to be functional.
Although restriction digest analysis is an efficient tech-
nique to analyze editing frequency, the restriction digest
analysis does not offer complete information about the
nature of the indels present at the EZH2 locus. For ex-
ample, in-frame indels or single base alterations could
appear as disruptions by restriction digest, but might not
affect protein function. To examine this further, we used
fluorescent fragment length analysis on a subset of the
clones that had been analyzed by restriction digest. In
the RD cells, all of the clones had at least one of the
three EZH2 alleles edited (a fragment length smaller or
greater than 394 bp), and in over half of the clones, all
three alleles had been edited resulting in out-of-frame
indels (Fig. 3a and Additional file 1: Figure S4). Con-
versely, in the EZH2-dependent cell lines, almost all
clones had at least one fragment length that was 394 bp,
indicating the presence of un-edited or in-frame
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alterations (Fig. 3b, c and d and Additional file 1: Figure
S4). The rare clones in the EZH2-dependent cells that
seemed to have no PCR products of wild-type length
were those in which the fragment lengths scored just
below 394 bp or just above 394 bp (Additional file 1:
Figure S4), which could be caused by fragment length
analysis assay imprecision.
To understand better the reason why some clones ap-
pear as homozygous disrupted in the digest assay but
heterozygous disrupted in the fragment length assay, we
sequenced the relevant PCR products. Four examples
are shown in Table 1. In both of the examples from the
G-401 cells, one allele of EZH2 is disrupted by a deletion
(16 bp and 47 bp, respectively) and the other allele in
both clones has a single nucleotide change that disrupts
the Fau1 site. Both alleles have been edited and the re-
striction digest in these clones correctly indicated a
homozygous disruption, and the fragment length PCR
also indicated correctly the presence of an allele of
undisrupted length. The sequencing confirmed that
these clones have retained an in-frame EZH2 allele. In
the two KYM-1 clones, both alleles have also been edi-
ted. Again, the restriction digest data indicated homozy-
gous edited alleles for both clones. For clone C, the
fragment length analysis indicated one edited allele and
one allele of 394 bp. In this case the sequencing data in-
dicated an in-frame 3 bp alteration. Clone D from KYM-
1 cells showed both fragment lengths corresponded with
an un-edited fragment length, and this was confirmed by
the sequence data, which showed a single nucleotide al-
teration in both alleles; this mutation disrupts the FauI
site, but retains the reading frame, suggesting that EZH2
remains expressed (and likely functional) in these clones.
The sequencing data also allowed us to be sure that the
detection of a PCR product that was just above or just
below 394 bp represented alleles in which single in-
frame nucleotide changes had occurred: this is reflected
in the summary graph and pie charts in Fig. 3, where all
clones from EZH2 dependent cell lines were verified as
having at least one allele of 394 bp. Interestingly, the
sequencing data combined with the fragment length
analyses (Fig. 3, Table 1 and Additional file 1: Figure S4)
also indicate that some of the clones from the EZH2-
dependent cell lines might have originated from the same
precursor cells, further indicating that the clones that
grow out in EZH2-dependent cell lines represent a small
proportion of the original cell population.
Thus, the combined analyses of the restriction digest
data and the fragment length data help to clearly define
the zygosity of the clonal cells, allowing for confirmation
of EZH2 dependent and non-dependent cell lines.
Sequencing analysis can also be used to indicate the
presence or absence of an in-frame allele.
Discussion
CRISPR–Cas9 editing of specific loci offers an alterna-
tive method to RNAi and small molecule inhibitors for
determining whether or not a cell line is dependent on a
specific gene product for proliferation and/or survival.
Our initial data indicated that knockout of EZH2 using
CRIPSR–Cas9 in a cell line that is dependent on EZH2
function for proliferation resulted in an expected prolif-
eration defect. However, growth of this cell population
over a prolonged period indicated that this effect was
transient, most likely owing to the outgrowth of cells in
which EZH2 function remains intact. In order to test our
hypothesis that the cells that grow out after 20 days are
those in which EZH2 has either not been targeted, or in
which the indels lead to in-frame alterations, we devel-
oped a medium throughput assay to analyze 10s–100s of
clones for gene essentiality.
The results from our gene essentiality assay clearly show
that in cell lines that are EZH2-independent, prolifer-
ation rates are unaltered, and the majority of clones
have EZH2 alleles that have been edited such that
EZH2 function is likely lost. Conversely, in all three
dependent cell lines, fewer clones survive the gene
knockout process. Of those that do, retention of an
in-frame or wild-type copy of one allele is observed in
every clone. Thus, the combined analyses of the restriction
(See figure on previous page.)
Fig. 2 Assay work flow summary for single cell CRISPR-Cas9 essentiality assay. Cells are infected with pLentiCRISPR containing Cas9 and a validated
sgRNA targeting a gene of interest. After virus infection, the cells are selected with puromycin for a minimum of 2 weeks before single cell dilution in
384-well plates. Blue wells labeled with two “XX” indicate cells with homozygous disrupted alleles, orange with “X” indicate cells with heterozygous
disrupted alleles, and yellow indicate cells in which the target alleles are unedited. Two medium-throughput methods are used to examine the
zygosity of the gene of interest in each of the isolated clones. For the restriction digest, the region around the sgRNA target site is amplified by
PCR and subject to restriction digest. PCR primers are chosen such that DNA fragments of unequal length are produced if the restriction
site remains intact. Alleles that have been edited should have the restriction site disrupted (represented by the green band) and therefore
will not be cut by the restriction enzyme. Unedited alleles (represented by the pink band) should retain an intact restriction site and should
be cut by the restriction enzyme. The gel shows examples of clones in which both alleles have been edited (blue asterisk), one allele has
been edited (orange asterisk) and no alleles have been edited (yellow asterisk). Fluorescent fragment length analyses are also used to assess
indel status. PCR primers that incorporate a fluorescent tag are used to amplify an area around the sgRNA binding sequence and the Cas9
cut site (indicated by the pink band). A fragment of un-edited length suggests a lack of disruption, whereas a fragment that is either longer
or shorter than the un-edited length suggests the presence of an indel (indicated by the green band)
Grassian et al. Biological Procedures Online  (2015) 17:15 Page 6 of 10
digest data and the fragment length data help to clearly
define the zygosity of the clonal cells, allowing for con-
firmation of EZH2-dependent and non-dependent cell
lines. Sequencing analysis can also be used to indicate the
presence or absence of an in-frame allele.
Although this assay can be used to help identify genes
that are essential for the growth of specific cancer cell
lines, it can also be used to determine whether a gene of
interest is likely to be a poor drug target owing to its es-
sentiality in many different cell lines (i.e. broad essential-
ity would be indicative of potential safety issues in the
clinic). Therefore, our gene essentiality assay is applic-
able to diseases other than cancer. There are specific
considerations that need to be addressed when using this
assay. First, the sgRNAs chosen for this assay need to be
assessed before-hand, specifically showing that they lead
to a substantial decrease in target expression and that
there are no proliferation effects that are due to off-
target effects. In our work with EZH2 we were able to
choose a sgRNA that was validated in a cell line in
which EZH2 is not required for proliferation. This might
be challenging to address for genes of interest in which
no target-independent cell line has been identified.
There are several algorithms that allow potential off-
target binding sites to be assessed for each potential
sgRNA and as CRIPSR–Cas9 screens become more
widely used, the data generated from these screens
should prove useful for the identification of guides that
do not have off-target proliferation effects. Second, some


















Fig. 3 Restriction digest data qualified by fragment length analyses. a-d Collated percentages of homozygous edited, heterozygous and
homozygous un-edited clones in each cell line. For each cell line, the top graph shows the restriction digest data and the bottom graph shows
the fragment length analysis data. The actual numbers of clones analyzed are shown on top of each bar. The pie chart at the bottom of each cell
line panel indicates the zygosity of the clones analyzed by the combined approaches of restriction digest and PCR fragment length analyses. Note
that RD cells have 3 copies of EZH2, whereas G-401, G-402 and KYM-1 cells have two copies
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tissue culture plastic, but are essential for growth in soft
agar or other matrix conditions [28–30]. Such an effect
would be missed in our current assay, but could be eas-
ily addressed by including single cell assays in alternative
tissue culture conditions. Third, as it is currently config-
ured, this assay cannot be used in cell lines that do not
grow or survive as single cells, thus probably limiting its
use for primary cells and patient samples. Finally, although
this assay can identify indels induced by Cas9 editing, it
does not test for enzymatic function of these mutations.
Conclusions
These findings highlight an important caveat to the use
of CRISPR–Cas9 for target identification and validation,
and present a robust assay to overcome these challenges.
We have developed a novel medium-throughput assay to
analyze gene essentiality in cell lines that are amenable to
single cell dilution cloning. This method should aid both
the understanding of whether the protein from a target
gene of interest needs to be completely absent for a pheno-
typic effect or whether reduced expression is sufficient to
induce the phenotype of interest. Such data will support
the development of more robust cancer therapeutics.
Methods
Vector Construction and Virus Production
sgRNA pRSGC1-U6-sg-CMV-Cas9-2A-Puro plasmid and
lentivirus for Figs. 1 and 2 were purchased from Cellecta.
Table 1 Sequencing allows further refinement of zygosity
Sequence analysis of specific clones to verify the status of EZH2 alleles. In both of the examples from the G-401 cell clones (A and B), one allele of EZH2 is disrupted by a
deletion (16 bp in clone A and 47 bp in clone B) and the other allele in both clones has a 1 bp mutation that disrupts the Fau1 site. Both alleles have been edited and
the restriction digest in these clones correctly indicated a homozygous disruption: the fragment length PCR analysis also indicated correctly the presence of an allele of
undisrupted length. The sequencing data shows that in all probability these clones have retained a functional EZH2 allele owing to an in frame mutation. In both of the
KYM-1 clones (C and D), both alleles have been edited. Again, the digest data correctly indicated homozygous edited alleles for both clones. For clone C, the fragment
length analysis indicated heterozygous edited alleles which was confirmed by the sequencing data showing one allele with an in frame 3pb alteration. Clone D from
KYM-1 cells showed both fragment lengths corresponded with an un-edited fragment length, and this was confirmed by the sequence data, which showed a 1 bp
alteration in both alleles. This explains why the restriction digest indicated homozygous edited alleles because the restriction digest site is mutated in both cases. These
data also suggest that EZH2 remains expressed in these clones
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The sequences for the sgRNA’s are as follows: EZH2
sgRNA #1 ACCGGGGAAGCAGGGACTGAAACG; EZH2
sgRNA #2 ACCGGGTCCCAATTAACCTAGCAA; EZH2
sgRNA #3 ACCGGTGGTGGATGCAACCCGCAA. For
additional studies, sgRNA #3 sequence was cloned into
pLentiCrispr v2 at DNA 2.0 [31]. HEK293T cells were
transfected with the pLentiCrispr-sgEZH2 construct and
Virapower packaging system using Lipofectamine 3000
(Life Technologies). Media was replaced with DMEM,
10 % FBS, 1 % BSA after 6 h and harvested 65 h later.
Viral particles were concentrated using Lenti-X concen-
trator (Clontech).
Immunoblotting
Cells were lysed in RIPA buffer containing 10 % SDS and
cOmplete Protease Inhibitor Cocktail Tablets (Roche). Ly-
sates were spun at 16,000 × g at 4 °C for 30 min and nor-
malized for protein concentration. Lysates were separated
using SDS-PAGE, and transfer/blotting was performed as
described previously [32]. Blots were imaged by fluores-
cent imaging using the Odyssey infrared imaging system
(LI-COR Biosciences; Millennium Science, Surrey Hills,
Australia). The following antibodies were used: EZH2
(Cell Signaling #3147), H3K27Me3 (Cell Signaling #9733)
and total H3 (Cell Signaling #3683).
Incucyte Proliferation Assays
Cells were plated in triplicate in 96 well plates and con-
fluency measurements were taken every 2 h using an
Incucyte Kinetic Imaging System (Essen BioScience).
Functional Titration and Spinfection of Cell Lines
Cells were spinfected by placing one million cells per
well in four wells of a 12 well plate in media containing
8 μg/ml polybrene. Multiple concentrations of virus
(0–40 μl) were added and the plate was centrifuged at
568 xg for 2 h at 37 °C. Virus containing media was then
removed and replaced with 1 ml of media without poly-
brene prior to incubation at 37 °C. The following day,
cells were trypsinized and the cell suspension was di-
vided into two wells of a 6-well plate and a lethal dose
of puromycin (0.4 μg/ml) was added to one well.
Seventy-two hours after plating, cells were trypsinized
and counted and the percent age of transduced cells was
determined. Cells infected with the optimal volume of
virus were maintained for 17 days in puromycin prior to
plating for single cell colonies.
Single Cell Dilution of Cell Lines
All four cell lines had been previously evaluated for their
ability to robustly grow from single cells. On the day of
plating, cells were trypsinized, counted, diluted to a
density of 0.75 and 1.5 cell per well and plated in five
384-well plates at each density by Multidrop dispenser
(Thermo Scientific). Plates were imaged using a Cell
Metric™ within 6 h of seeding, at intervals of seven days
and at the time of harvest. When colonies had reached
sufficient size (at least 25 % well confluence), data from
the Cell Metric™ was used to generate a pick list for each
cell line. Colonies were trypsinized and consolidated
from multiple plates into a single 384-well plate for each
cell line using a Hamilton Microlab Star robotic system.
Samples were immediately lysed in DirectPCR lysis
reagent (Viagen).
Restriction Digest Analysis of EZH2 Targeted Colonies
The region around the Cas9 cut site targeted by the
sgRNA was amplified by PCR. Primers used were as fol-
lows; forward AGGCAAACCCTGAAGAACTG, reverse
ATGGCTCTCTTGGCAAAAAT. PCR products were
digested with the restriction enzyme FauI, which directly
overlapped the Cas9 cut site for the sgRNA targeting
EZH2. Digested PCR products were resolved by agarose
gel electrophoresis and assessed for the genotype of dis-
ruption of the FauI cut site (heterozygous disrupted,
homozygous disrupted or homozygous un-disrupted).
Fragment Length Analysis
The region around the Cas9 cut site targeted by the
sgRNA in either EZH2 or the ROSA26 locus was ampli-
fied by PCR using primers of the same sequence as for
the digest analysis, with the forward primer tagged with
FAM. Resultant PCR products were purified using
Diffinity RapidTips (Sigma) and diluted 1:50 in H2O. Ca-
pillary electrophoresis was performed on the samples
(Source Biosciences) using Liz-600 size standards;
fragment length was determined using Genemapper5
software (Applied Biosystems).
Additional File
Additional file 1: Figure S1. Data relating to EPZ007210. Table S1.
Verification that the cell lines used in the assay can grow from single
cells. Figure S2. Restriction assay details. Figure S3. G-401 clones Figure
S4. Fluorescent PCR fragment length raw data. (PDF 1729 kb)
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